According to the Smart Finance APP, Circ (01763) announced that on November 14, 2024, the company's subsidiary Atomic High-Tech's wholly-owned subsidiary, Atomic High-Tech North China Pharmaceutical Co., Ltd. (North China High-Tech), successfully obtained the radiation safety license issued by the Ministry of Eco-friendly concept.

The North China High-Tech project is planned to occupy an area of approximately 85.8 acres and will have advanced automated production lines for various radioactive pharmaceuticals, as well as an integrated quality control laboratory throughout the entire process, leading the pharmaceutical industry towards automation, asia vets, and scale, showcasing the strong strength and forward-looking layout of the China National Nuclear Corporation in the field of radioactive drugs. After its completion, North China High-Tech will become the largest isotope pharmaceutical production base in Asia, with the most product varieties and the most advanced technology, achieving a transfer of radioactive drug production and an enhancement in technical level, increasing the supply capacity of radioactive drugs and accelerating industrial upgrading.